Stay tuned on the latest company news and upcoming events

MARCH 24, 2022
Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease

FEBRUARY 14, 2022
Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Conference

FEBRUARY 1, 2022
Azafaros Receives FDA Orphan Drug Designation for AZ-3102 in GM2 Gangliosidosis

JANUARY 18, 2022
Azafaros Announces Multiple Presentations at 18th Annual WORLDSymposium™

JUNE 30, 2021
Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer

APRIL 06, 2021
Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorderss

JUNE 10, 2020
Azafaros expands executive management team and operations

FEBRUARY 06, 2020
Azafaros completes EUR 25 million Series A financing to advance rare metabolic disorders pipeline

JULY 23, 2018
Azafaros B.V. secures seed funding to develop new treatments in rare metabolic disorders

Swiss Biotech Day 2022, May 2-3, 2022
Basel
Meeting Website

LSX World Congress, May 10-11, 2022
London
Meeting Website